Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Sponsor
Sun Yat-sen University
Study ID
NCT03144856
Phase
PHASE2
Status
Unknown

Conditions

  • Biliary Tract Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500mg, po, qd, every 4 weeks.

Study Details

This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.

Key Dates

Start date
Feb 22, 2017
Status verified
May 2017
Primary completion
Mar 1, 2019
Completion
Mar 1, 2019

Study Design

Enrollment
39 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib group
    Apatinib 500mg, po, QD, every 4 weeks.

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: Approximately 1 year ]

Central Contacts

Related Studies